Skip to main content

Table 2 Statistics of patient data used for pharmacoepidemiologic analysis

From: Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease

Group Sample size # of AD Female (%) Mean Age (SD) Geographical location (%) CAD (%) T2D (%) HTN (%)
Northeast North Central South West NA
Pioglitazone (repurposing drug), glipizide (comparative drug) and matched control
Pioglitazone 101,650 1244 38.5 72.8 (6.9) 17.7 28.4 35.6 17.3 0.9 11.3 51.2 34.2
Glipizide 191,656 3048 44.8 74.2 (7.1) 21.5 27.6 31.4 18.7 0.8 17.1 59.4 43.0
Control 402,488 5230 38.3 74.5 (7.2) 24.2 31.4 30.5 13 1 13.5 44.6 41.1
Febuxostat (repurposing drug), and matched control
Febuxostat 24,218 243 37.2 75.1 (7.9) 23.5 23.8 37.7 14.4 0.6 28.0 35.3 58.6
Control 95,192 1168 37.0 75.7 (7.4) 24.7 31.6 30.3 12.7 0.8 26.7 34.1 58.1
Atenolol (repurposing drug), and matched control
Atenolol 366,277   58 74.5 (8.0) 24 26 29 21 0.7 11 14 34
Control 1,449,815   58 75.2 (7.5) 24 30 30 14 1.1 12 16 38
Nadolol (repurposing drug), and matched control
Nadolol 19,253   60 73.7 (7.8) 29 25 35 10 0.8 11 18 34
Control 76,136   60 75.2 (7.5) 24 30 30 14 1.1 12 19 40
Sotalol (repurposing drug), and matched control
Sotalol 43,819   46 76.4 (7.7) 19 29 38 14 0.5 35 22 50
Control 172,375   46 76.1 (7.5) 25 31 30 13 0.8 30 22 50
  1. We estimated the unstratified Kaplan-Meier curves, conducted propensity score stratified (n strata = 10) log-rank test and Cox model. CAD coronary artery disease, T2D type 2 diabetes, HTN hypertension, SD standard deviation